Corpus overview


MeSH Disease

Human Phenotype


    displaying 1 - 10 records in total 193
    records per page

    Severity detection for the coronavirus disease MESHD 2019 (COVID-19) patients using a machine learning model based on the blood SERO and urine tests

    Authors: Haochen Yao; Nan Zhang; Ruochi Zhang; Meiyu Duan; Tianqi Xie; Jiahui Pan; Ejun Peng; Juanjuan Huang; Yingli Zhang; Xiaoming Xu; Hong Xu; Fengfeng Zhou; Guoqing Wang

    doi:10.1101/2020.07.27.20044990 Date: 2020-07-29 Source: medRxiv

    The recent outbreak of the coronavirus disease MESHD-2019 (COVID-19) caused serious challenges to the human society in China and across the world. COVID-19 induced pneumonia MESHD pneumonia HP in human hosts and carried a highly inter-person contagiousness. The COVID-19 patients may carry severe symptoms, and some of them may even die of major organ failures. This study utilized the machine learning algorithms to build the COVID-19 severeness detection model. Support vector machine (SVM) demonstrated a promising detection accuracy after 32 features were detected to be significantly associated with the COVID-19 severeness. These 32 features were further screened for inter-feature redundancies. The final SVM model was trained using 28 features and achieved the overall accuracy 0.8148. This work may facilitate the risk estimation of whether the COVID-19 patients would develop the severe symptoms. The 28 COVID-19 severeness associated biomarkers may also be investigated for their underlining mechanisms how they were involved in the COVID-19 infections MESHD.

    Efficacy and tolerability of bevacizumab in patients with severe Covid -19

    Authors: Jiaojiao Pang; Feng Xu; Gianmarco Aondio; Yu Li; Alberto Fumagalli; Ming Lu; Giuseppe Valmadre; Jie Wei; Yuan Bian; Margherita Canesi; Giovanni Damiani; Yuan Zhang; Dexin Yu; Jun Chen; Xiang Ji; Wenhai Sui; Bailu Wang; Shuo Wu; Attila Kovacs; Miriam Revera; Hao Wang; Ying Zhang; Yuguo Chen; Yihai Cao

    doi:10.1101/2020.07.26.20159756 Date: 2020-07-29 Source: medRxiv

    On the basis of Covid-19-induced pulmonary pathological and vascular changes, we hypothesized that the anti-VEGF drug bevacizumab might be beneficial for treating Covid-19 patients. We recruited 26 patients from 2-centers (China and Italy) with confirmed severe Covid-19, with respiratory rate [≥]30 times/min, oxygen saturation [≤]93% with ambient air, or partial arterial oxygen pressure to fraction of inspiration O2 ratio (PaO2/FiO2) >100mmHg and [≤]300 mmHg, and diffuse pneumonia MESHD pneumonia HP confirmed by chest radiological imaging. This trial was conducted from Feb 15 to April 5, 2020, and followed up for 28 days. Relative to comparable control patients with severe Covid-19 admitted in the same centers, bevacizumab showed clinical efficacy by improving oxygenation and shortening oxygen-support duration. Among 26 hospitalized patients with severe Covid-19 (median age TRANS, 62 years, 20 [77%] males TRANS), bevacizumab plus standard care markedly improved the PaO2/FiO2 ratios at days 1 and 7 (elevated values, day 1, 50.5 [4.0,119.0], p<0.001; day 7, 111.0 [85.0,165.0], p<0.001). By day 28, 24 (92%) patients showed improvement in oxygen-support status, 17 (65%) patients were discharged, and none showed worsen oxygen-support status nor died. Significant reduction of lesion areas and ratios were shown in chest CT or X-ray analysis within 7 days. Of 14 patients with fever MESHD fever HP, body temperature normalized within 72 hours in 13 (93%) patients. Lymphocyte counts in peripheral blood SERO were significantly increased and CRP levels were markedly decreased as shown in available data. Our findings suggested bevacizumab plus standard care was highly beneficial for treating patients with severe Covid-19. Clinical efficacy of bevacizumab warrants double blind, randomized, placebo-controlled trials.

    Patients with COVID-19 Interstitial Pneumonia MESHD Pneumonia HP Exhibit Pancreatic Hyperenzymemia and Not Acute Pancreatitis HP Pancreatitis MESHD

    Authors: Raffaele Pezzilli; Stefano Centanni; Michele Mondoni; Rocco F. Rinaldo; Matteo Davì; Rossana Stefanelli; GianVico Melzi d’Eril; Alessandra Barassi

    doi:10.21203/ Date: 2020-07-28 Source: ResearchSquare

    Background and aims: Gastrointestinal manifestations of COVID-19 have been well established, but pancreatic involvement is under debate. The aim of the study is to evaluate the presence of acute pancreatitis HP pancreatitis MESHD in COVID-19 patients and to assess the frequency of pancreatic hyperenzymemia. Methods: From April 1st 2020 to April 30th 2020, 110 consecutive patients (69 males TRANS, 41 females TRANS; mean age TRANS 63.0 years, range 24-93 years) met these criteria and were enrolled in the study.. The clinical data and serum SERO activity of pancreatic amylase and lipase were assayed in all patients using commercially available kits. Results: None of the patients studied developed clinical signs or morphological alterations compatible with acute pancreatitis HP pancreatitis MESHD. However, it was found that 24.5% of the patients had amylase values above 53 IU/L and 16.4% had lipase values above 300 IU/. Only one patient (0.9%) had both amylase and lipase values in excess of three-fold the upper normal limit without clinical signs of pancreatitis MESHD pancreatitis HP. Conclusions: The presence of pancreatic hyperenzymemia in a patient with COVID-19 requires the management of these patients be guided by clinical evaluation and not merely by evaluation of the biochemical results.

    Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia MESHD pneumonia HP treated with high-titer convalescent plasma SERO: a prospective study

    Authors: Michele Donato; Steven Park; Melissa Baker; Robert Korngold; Alison Morawski; Xue Geng; Ming Tony Tan; Scott Rowley; Kar Chow; Emily Brown; Joshua Zenreich; Phyllis McKiernan; Kathryn Buttner; Anna Ullrich; Laura Long; Marlo Kemp; Mariefel Vendivil; Andrea Ricourt; Rena Feinman; Hyung Suh; Balani Bindu; Cristina Cicogna; Rani Sebti; Abdulla Al-Khan; Steven Sperber; Samit Desai; Stacey Fanning; Danit Arad; Ronaldo Go; Elizabeth Tam; Keith Rose; Sean Sadikot; David S Siegel; Martin Gutierrez; Andrew Ip; Stuart Goldberg; Tatyana Feldman; Andre Goy; Andrew Pecora; Noa Biran; Lori Leslie; Alfred Gillio; Sarah Timmapuri; Michele Boonstra; Samuel Singer; Sukhdeep Kaur; Ernest Richards; David Perlin

    doi:10.1101/2020.07.20.20156398 Date: 2020-07-26 Source: medRxiv

    Background Effective antiviral therapy against the severe acute respiratory syndrome MESHD virus 2 (SARS-CoV-2) remains elusive. Convalescent plasma SERO is an anti-viral approach currently under investigation. We aimed to assess the laboratory and clinical parameters of patients with COVID-19 pneumonia MESHD pneumonia HP treated with convalescent plasma SERO containing high levels of neutralizing anti- SARS-CoV-2 antibodies SERO.

    Dysregulated transcriptional responses to SARS-CoV-2 in the periphery support novel diagnostic approaches

    Authors: Micah T McClain; Florica J Constantine; Ricardo Henao; Yiling Liu; Ephraim L Tsalik; Thomas W Burke; Julie M Steinbrink; Elizabeth Petzold; Bradly P Nicholson; Robert Rolfe; Bryan D Kraft; Matthew S Kelly; Gregory D Sempowski; Thomas N Denny; Geoffrey S Ginsburg; Christopher W Woods

    doi:10.1101/2020.07.20.20155507 Date: 2020-07-26 Source: medRxiv

    In order to elucidate novel aspects of the host response to SARS-CoV-2 we performed RNA sequencing on peripheral blood SERO samples across 77 timepoints from 46 subjects with COVID-19 and compared them to subjects with seasonal coronavirus, influenza, bacterial pneumonia MESHD pneumonia HP, and healthy controls. Early SARS-CoV-2 infection MESHD triggers a conserved transcriptomic response in peripheral blood SERO that is heavily interferon-driven but also marked by indicators of early B-cell activation and antibody SERO production. Interferon responses during SARS-CoV-2 infection MESHD demonstrate unique patterns of dysregulated expression compared to other infectious and healthy states. Heterogeneous activation of coagulation and fibrinolytic pathways are present in early COVID-19, as are IL1 and JAK/STAT signaling pathways, that persist into late disease MESHD. Classifiers based on differentially expressed genes accurately distinguished SARS-CoV-2 infection MESHD from other acute illnesses (auROC 0.95). The transcriptome in peripheral blood SERO reveals unique aspects of the immune response in COVID-19 and provides for novel biomarker-based approaches to diagnosis.

    High neutralizing potency of swine glyco-humanized polyclonal antibodies SERO against SARS-CoV-2

    Authors: Bernard Vanhove; Odile Duvaux; Juliette Rousse; Pierre-Joseph Royer; Gwenaelle Evanno; Carine Ciron; Elsa Lheriteau; Laurent Vacher; Nadine Gervois; Romain Oger; Yannick Jacques; Apolline Salama; Roberto Duchi; Andrea Perota; Philippe Delahaut; Matthieu Ledure; Melody Paulus; Ray So; Chris Ka Pun Mok; Roberto Bruzzone; Marc Bouillet; Sophie Brouard; Emanuele Cozzi; Cesare Galli; Dominique Blanchard; Jean-Marie Bach; Jean-Paul Soulillou

    doi:10.1101/2020.07.25.217158 Date: 2020-07-25 Source: bioRxiv

    Perfusion of convalescent plasma SERO (CP) has demonstrated a potential to improve the pneumonia MESHD pneumonia HP induced by SARS-CoV-2, but procurement and standardization of CP are barriers to its wide usage. Heterologous polyclonal antibodies SERO of animal origin have been used to fight against infectious agents and are a possible alternative to the use of CP in SARS-CoV-2 disease MESHD. However, heterologous polyclonal antibodies SERO trigger human natural xenogeneic antibody SERO responses particularly directed against animal-type carbohydrate epitopes, mainly the N-glycolyl form of the neuraminic acid (Neu5Gc) and the Gal alpha1,3-galactose (a-Gal), ultimately forming immune complexes and potentially leading to serum sickness MESHD serum SERO or allergy HP. To circumvent these drawbacks, we engineered animals lacking the cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMAH) and alpha1,3-galactosyltransferase (GGTA1) enzymes to produce glyco-humanized polyclonal antibodies SERO (GH-pAb) lacking Neu5Gc and a-Gal epitopes. We also found that these IgG Fc domains fail to interact with human Fc receptors and thereby should confer the safety advantage to avoiding macrophage dependent exacerbated inflammatory responses or elicit antibody SERO-dependent enhancement (ADE), two drawbacks possibly associated with antibody SERO responses against SARS-CoV-2. Therefore, we immunized CMAH/GGTA1 double knockout (DKO) pigs with the SARS-CoV-2 spike receptor binding domain (RBD) domain to elicit neutralizing antibodies SERO. Animals rapidly developed hyperimmune sera with end-titers binding dilutions over one to a million and end-titers neutralizing dilutions of 1:10,000. The IgG fraction purified and formulated following clinical Good Manufacturing Practices, named XAV-19, neutralized Spike/ACE-2 interaction at a concentration < 1microgram/mL and inhibited infection MESHD of human cells by SARS-CoV-2 in cytopathic assays. These data and the accumulating safety advantages of using glyco-humanized swine antibodies SERO in humans warrant clinical assessment of XAV-19 to fight against COVID-19.

    Aneurysmal Subarachnoid Haemorrhage After COVID-19 Infection MESHD

    Authors: Sajjad Muhammad; Soheil Naderi; Mostafa Ahmadi; Askar Ghorbani; Daniel Hänggi

    doi:10.21203/ Date: 2020-07-24 Source: ResearchSquare

    BackgroundSARS-CoV-2 virus infection MESHD leads to a severe and dysbalanced inflammatory response with hypercytokinemia and immunodepression. Systemic inflammation MESHD due to viral infections MESHD can potentially cause vascular damage including disruption of blood SERO-brain barrier (BBB) and alterations in coagulation system that may also lead to cardiovascular and neurovascular events. Here, we report the first case of COVID-19 infection MESHD leading to aneurysmal subarachnoid haemorrhage (aSAH). Case DescriptionA 61-year-old woman presented with dyspnea MESHD dyspnea HP, cough MESHD cough HP and fever MESHD fever HP. She was over weight with Body MESHD mass-index of 34 and history of hypertension MESHD hypertension HP. No history of subarachnoid hemorrhage MESHD subarachnoid hemorrhage HP in the family. She was admitted in ICU due to low oxygen saturation (89%). A chest CT showed typical picture of COVID-19 pneumonia MESHD pneumonia HP. Oropharyngeal swab with a PCR-based testing was COVID-19 positive. She was prescribed with favipiravir and hydroxychloroquine in Addition to oxygen support. On second day she experienced sudden headache MESHD headache HP and losst conciousness. A computer tomography (CT) with CT-angiography revealed subarachnoid haemorrhage in basal cisterns from a ruptured MESHD anterior communicating artery aneurysm MESHD. The aneurysm MESHD was clipped microsurgically through a standard pterional approach and the patient was admitted again to intensive care unit for further intensive medical treatment. Post-operative the patient showed slight motor dysphasia HP. No other neurological deficits.ConclusionAneurysmal subarachnoid haemorrhage secondary to COVID-19 infection MESHD might be triggered by systemic inflammation MESHD. COVID-19 infection MESHD could be one of the risk factors leading to instability and rupture MESHD of intracranial aneurysm MESHD.

    Ocular findings and retinal involvement in COVID-19 pneumonia MESHD pneumonia HP patients: A cross-sectional study in an Italian referral centre

    Authors: Maria Pia Pirraglia; Giancarlo Ceccarelli; Alberto Cerini; Giacomo Visioli; Gabriella d'Ettorre; Claudio Maria Mastroianni; Francesco Pugliese; Alessandro Lambiase; Magda Gharbiya

    doi:10.21203/ Date: 2020-07-23 Source: ResearchSquare

    Background: changes in immune and coagulation systems and possible viral spread through blood SERO-brain barrier have been described in SARS-CoV-2 infection MESHD. In this study, we evaluate the possible retinal involvement and ocular findings in severe COVID-19 pneumonia MESHD pneumonia HP patients.  Methods: a cross sectional study was conducted on 46 patients affected by severe COVID-19 who were hospitalized in one Intensive Care Unit (ICU) and in two Infectious Diseases MESHD wards, including a bedside eye screening, corneal sensitivity SERO assessment and retinography. Results: a total of 43 SARS-CoV-2 positive pneumonia MESHD pneumonia HP patients affected with COVID-19 pneumonia MESHD pneumonia HP were included, 25 males TRANS and 18 females TRANS, with a median age TRANS of 70 [IQR 59-78]. Except for one patient with unilateral posterior chorioretinitis MESHD chorioretinitis HP of opportunistic origin, of whom aqueous tap was negative for SARS-CoV-2, no further retinal manifestation related to COVID-19 infection MESHD was found in our cohort. We found 3 patients (7%) with bilateral conjunctivitis MESHD conjunctivitis HP in whom PCR analysis on conjunctival swab provided negative results for SARS-CoV-2. No alterations of corneal sensitivity SERO were found.Conclusion: we demonstrated the absence of retinal involvement in SARS-CoV-2 pneumonia MESHD pneumonia HP patients. Ophthalmologic evaluation in COVID-19, particularly in patients hospitalized in an ICU setting, may be useful to reveal systemic co- infections by opportunistic MESHD infections by opportunistic HP pathogens. 

    Serum SERO cholinesterase on admission as a predictor of COVID-19 pneumonia MESHD pneumonia HP severity and mortality

    Authors: Kento Nakajima; Takeru Abe; Ryo Saji; Fumihiro Ogawa; Hayato Taniguchi; Keishi Yamaguchi; Kazuya Sakai; Tomoki Nakagawa; Reo Matsumura; Yasuhumi Oi; Mototsugu Nishii; Ichiro Takeuchi

    doi:10.21203/ Date: 2020-07-22 Source: ResearchSquare

    Background Although some predictors of COVID-19 pneumonia MESHD pneumonia HP severity and mortality have been identified, much of the pathophysiology of this emerging infectious disease MESHD remains unclear. We hypothesized that a patient’s cholinesterase level on admission could predict COVID-19 pneumonia MESHD pneumonia HP severity and mortality.Methods We retrospectively collected data of 26 COVID-19 pneumonia MESHD pneumonia HP patients from February–May 2020. Outcomes were aggravation of symptoms and in-hospital mortality. We compared receiver operating curves of cholinesterase, C-reactive protein, lymphocytes, albumin, D-dimer, and PaO2/FiO2 ratio and examined prediction accuracy. Regarding the interaction between cholinesterase and other variables, each independent variable was divided into two groups using cutoff values, and interaction terms were created.Results Cholinesterase levels on admission were significantly lower in the severe group than in the mild-to-moderate group (326 vs. 218 IU/L, p = 0.006; area under the curve: 0.81; 95% confidence interval 0.61–0.94). When comparing the area under the curve, cholinesterase was comparable to C-reactive protein, albumin, lymphocytes, and PaO2/FiO2 ratio other than D-dimer in the prediction accuracy of severe cases and mortality. Cholinesterase levels on admission were significantly lower in the death MESHD group than in the survival group (274 vs. 187.5 IU/L, p = 0.028; area under the curve: 0.79; 95% interval 0.58–0.93). Regarding the interaction between cholinesterase and established predictors, the prediction accuracy of both severity and death MESHD was higher when cholinesterase was combined with each predictor than when cholinesterase was used alone.Conclusions Cholinesterase may reflect the disease MESHD state of COVID-19 pneumonia MESHD pneumonia HP, suggesting that a patient’s cholinesterase level on admission may be useful as a predictor of severity and prognosis.

    Single cell RNA sequencing of blood SERO antigen-presenting cells in severe Covid-19 reveals multi-process defects in antiviral immunity

    Authors: Melissa Saichi; Maha Zohra Ladjemi; Sarantis Korniotis; Christophe Rousseau; Zakaria Ait-Hamou; Lucile Massenet; Elise Amblard; Floriane Noel; Yannick Marie; Delphine Bouteiller; Jasna Medvedovic; Frederic Pene; Vassili Soumelis

    doi:10.1101/2020.07.20.212837 Date: 2020-07-21 Source: bioRxiv

    COVID-19 can lead to life-threatening acute respiratory failure HP, characterized by simultaneous increase in inflammatory mediators and viral load. The underlying cellular and molecular mechanisms remain unclear. We performed single-cell RNA-sequencing to establish an exhaustive high-resolution map of blood SERO antigen-presenting cells (APC) in 7 COVID-19 patients with moderate or severe pneumonia MESHD pneumonia HP, at day-1 and day-4 post-admission, and two healthy donors. We generated a unique dataset of 31,513 high quality APC, including monocytes and rare dendritic cell (DC) subsets. We uncovered multiprocess and previously unrecognized defects in anti-viral immune defense in specific APC compartments from severe patients: i) increase of pro-apoptotic genes exclusively in pDC, which are key effectors of antiviral immunity, ii) sharp decrease of innate sensing receptors, TLR7 and DHX9, in pDC and cDC1, respectively, iii) down-regulation of antiviral effector molecules, including Interferon stimulated genes (ISG) in all monocyte subsets, and iv) decrease of MHC class II-related genes, and MHC class II transactivator (CIITA) activity in cDC2, suggesting a viral inhibition of antigen presentation. These novel mechanisms may explain patient aggravation and suggest strategies to restore defective immune defense.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).



MeSH Disease
Human Phenotype

Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.